ERBB2 and breast cancer: Finally, we reasoned that if a higher rate of apoptosis is responsible for the reduced tumorigenic properties observed upon USP22 loss in HER2+-BC, the inhibition of caspase activity should, at least partially, rescue the impaired phenotype.